RxDoctor Payments Data

William Farr, MD

Family Medicine · Bakersfield, CANPI 1215926100

Payments from drug & device makers

$6,335in general payments, 2019–2025

Across 381 payments — averaging $16.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$883
  • Nestle Healthcare Nutrition Inc.$603
  • Aimmune Therapeutics, Inc.$512
  • Pfizer$497
  • Daiichi Sankyo Inc.$485
  • AstraZeneca$466
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$6,335100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,335 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$711,009
Medicare patients
1,553
Services billed
29,988

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide58$65,369
MounjaroTirzepatide50$50,664
JardianceEmpagliflozin27$35,717
FarxigaDapagliflozin Propanediol28$29,820
EliquisApixaban23$23,035
MyrbetriqMirabegron23$19,690
XareltoRivaroxaban17$15,979
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$10,640
PaxlovidNirmatrelvir/Ritonavir44$4,288
Atorvastatin Calcium258$3,109
SynthroidLevothyroxine Sodium28$2,673
Rosuvastatin Calcium222$2,662
Olmesartan Medoxomil90$2,656
Ezetimibe49$2,543
Testosterone22$2,438

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$883$65,36958 claims
Lilly USA, LLCMounjaro$262$50,66450 claims
Boehringer IngelheimJardiance$208$35,71727 claims
AstraZenecaFarxiga$466$29,82028 claims
PfizerEliquis, Paxlovid$497$27,32267 claims
Astellas Pharma US IncMyrbetriq$82$19,69023 claims
Johnson & JohnsonXarelto$32$15,97917 claims
GSKTrelegy Ellipta$167$10,64018 claims
AbbVieSynthroid$465$2,67328 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →